Hematology/Oncology

Top Story

NCI grant to fund AML research at City of Hope

NCI grant to fund AML research at City of Hope
April 29, 2016

The NCI awarded a $2.3 million grant to a research team at City of Hope led by Steven T. Rosen, MD, the institution’s provost and chief scientific officer.

The grant will fund studies associated with a phase 1/phase 2 clinical trial of 8-chloro-adenosine in relapsed/refractory adult acute myeloid leukemia.

In the Journals

Increased frequency of unknown primary SCC linked to HPV–positive disease

April 29, 2016
HPV–positive unknown primary squamous cell carcinoma (UPSCC) appeared to be most prevalent among younger men, results showed.
In the Journals

ACP: Physicians can help tackle public health threat of climate change

April 29, 2016
Climate change poses a significant threat to public health and needs to be addressed by drastic actions in part by physicians and the health care community, according to…
Video

VIDEO: Genomic assays have role in determining need for adjuvant chemotherapy

April 29, 2016
The use of genomic assays for determining which patients with breast cancer require adjuvant chemotherapy has been “a matter of some debate for at least a…
In the Journals

CT colonography comparable to flexible sigmoidoscopy for CRC screening

April 29, 2016
CT colonography performed with a comparable detection rate to flexible sigmoidoscopy as a screening test for colorectal cancer in two randomized clinical trials in…
More News Headlines »
CME Video

World Lung Updates: Immunotherapy in NSCLC

This activity is supported by an educational grant from Genentech, Inc and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for…
More »
Video

VIDEO: Genomic assays have role in determining need for adjuvant chemotherapy

April 29, 2016
More »
Featured
At Issue: Multiple Myeloma Resource Center

At Issue: Multiple Myeloma Resource Center

CME

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease…
More »
Current Issues
View the Current Issue
HemOnc Today